Portal de investigación
SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Llau, JV
- Sierra, P
- Hidalgo, F
- Cassinello, C
- Gomez-Luque, A
- Quintana, M
- Amezaga, R
- Gero, M
- Serrano, A
- Marcos, P
Grupos
Abstract
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID19, mainly causes alterations in the respiratory system. In severely ill patients, the disease oftenevolves into an acute respiratory distress syndrome that can predispose patients to a state ofhypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatoryprocess linked to this pathology, including the additional thrombotic factors present in many ofthe patients. In view of the need to optimise the management of hypercoagulability, the working groupsof the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and ofIntensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observedin severely ill patients with COVID-19. These recommendations include prophylaxis of venousthromboembolic disease in these patients, and in the peripartum, management of patients onlongterm antiplatelet or anticoagulant treatment, bleeding complications in the course of thedisease, and the interpretation of general alterations in haemostasis. (c) 2020 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Anestesiologia, Reanimacion y Terap ' eutica del Dolor.
Datos de la publicación
- ISSN/ISSNe:
- 0034-9356, 2340-3284
- Tipo:
- Article
- Páginas:
- 391-399
- PubMed:
- 32591185
- Factor de Impacto:
- 0,337 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Revista espanola de anestesiologia y reanimacion ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 11
Documentos
- No hay documentos
Filiaciones
Keywords
- COVID-19; Coronavirus infections; Low-molecular-weight heparin; Anticoagulants; Anti-platelets; Thrombosis; Pregnancy complications
Proyectos y Estudios Clínicos
ENSAYO DE FASE III, ALEATORIZADO, DOBLE CIEGO, MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE OCTAPLEX, UN CONCENTRADO DE COMPLEJO DE PROTROMBINA DE CUATRO FACTORES (CCP-4F), EN COMPARACIÓN CON EL CCP-4F BERIPLEX® P/N (KCENTRA), PARA LA REVERSIÓ N DE LA ANTICOAGULACIÓN INDUCIDA POR ANTAGONISTAS DE LA VITAMINA K EN PACIENTES QUE REQUIEREN UNA INTERVENCIÓN QUIRÚRGICA DE URGENCIA Y QUE TIENEN UN RIESGO SIGNIFICATIVO DE HEMORRAGIA.
Investigador Principal: MARÍA AZUCENA PAJARES MONCHO
LEX-209 . 2017
Cita
Llau JV,FERRANDIS R,Sierra P,Hidalgo F,Cassinello C,Gomez A,Quintana M,Amezaga R,Gero M,Serrano A,Marcos P. SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection. Rev. Esp. Anestesiol. Reanim. 2020. 67. (7):p. 391-399.